1. Home
  2. RNTX vs NINE Comparison

RNTX vs NINE Comparison

Compare RNTX & NINE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNTX
  • NINE
  • Stock Information
  • Founded
  • RNTX 2001
  • NINE 2011
  • Country
  • RNTX United States
  • NINE United States
  • Employees
  • RNTX N/A
  • NINE N/A
  • Industry
  • RNTX Biotechnology: Pharmaceutical Preparations
  • NINE Oilfield Services/Equipment
  • Sector
  • RNTX Health Care
  • NINE Energy
  • Exchange
  • RNTX Nasdaq
  • NINE Nasdaq
  • Market Cap
  • RNTX 26.5M
  • NINE 23.8M
  • IPO Year
  • RNTX N/A
  • NINE 2018
  • Fundamental
  • Price
  • RNTX $1.34
  • NINE $0.69
  • Analyst Decision
  • RNTX Hold
  • NINE
  • Analyst Count
  • RNTX 1
  • NINE 0
  • Target Price
  • RNTX N/A
  • NINE N/A
  • AVG Volume (30 Days)
  • RNTX 65.2K
  • NINE 720.4K
  • Earning Date
  • RNTX 08-14-2025
  • NINE 10-30-2025
  • Dividend Yield
  • RNTX N/A
  • NINE N/A
  • EPS Growth
  • RNTX N/A
  • NINE N/A
  • EPS
  • RNTX N/A
  • NINE N/A
  • Revenue
  • RNTX N/A
  • NINE $577,300,000.00
  • Revenue This Year
  • RNTX N/A
  • NINE $4.56
  • Revenue Next Year
  • RNTX N/A
  • NINE $1.41
  • P/E Ratio
  • RNTX N/A
  • NINE N/A
  • Revenue Growth
  • RNTX N/A
  • NINE 3.23
  • 52 Week Low
  • RNTX $1.04
  • NINE $0.44
  • 52 Week High
  • RNTX $4.40
  • NINE $1.87
  • Technical
  • Relative Strength Index (RSI)
  • RNTX 49.84
  • NINE 54.57
  • Support Level
  • RNTX $1.06
  • NINE $0.54
  • Resistance Level
  • RNTX $1.21
  • NINE $0.67
  • Average True Range (ATR)
  • RNTX 0.10
  • NINE 0.05
  • MACD
  • RNTX 0.02
  • NINE 0.01
  • Stochastic Oscillator
  • RNTX 66.67
  • NINE 100.00

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

About NINE Nine Energy Service Inc.

Nine Energy Service Inc is a North American onshore completion and production services provider. It targets unconventional oil and gas resource development. It operates in one segment, Completion Solutions. The Completion Solutions segment offers cementing services; completion tools, including liner hangers and accessories, frac sleeves, fully composite frac plugs, and specialty open hole float equipment and centralizers and other services. It operates in the U.S, Canada, and other countries where majority of the revenue is generated from the United States.

Share on Social Networks: